Novo Nordisk A/S Class B Accounts Payable

The latest accounts payable for NONOF is $150B as of June 2026. That compares with $28B in the prior-year period — up 448.8% year over year. Investors often review this figure alongside Novo Nordisk A/S Class B's historical trend and sector peers before judging valuation or financial health.

Over the past year, NONOF's accounts payable moved from $28B to $150B — a 448.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Novo Nordisk A/S Class B's operating scale or balance-sheet position.

A accounts payable figure of $150B for NONOF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NONOF's accounts payable ($150B), review year-over-year change from $28B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Novo Nordisk A/S Class B's accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.